University of Texas Southwestern Medical Center

Open enrollment with an early-phase pipeline tilt

According to ClinicalTrials.gov-derived indexes, University of Texas Southwestern Medical Center sits in the top decile of US sponsors by registered trial count (#39 of 15,742 sponsors by registered trial count).

837 total trials 162 currently recruiting 503 completed early-phase tilt top decile by trial count

University of Texas Southwestern Medical Center: 837 sponsored US clinical trials, 162 recruiting.

University of Texas Southwestern Medical Center sponsors 837 registered US clinical trials on ClinicalTrials.gov, 162 of them currently recruiting, and 503 completed. 126 of these trials are in Phase 3-4 (later-stage) and 228 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Hypertension, with 9 trials.

Top-decile sponsor footprint

University of Texas Southwestern Medical Center ranks in the top decile of sponsors by registered trial count (#39 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Trial completion reliability score

F 46/100

503 of 608 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (82.7%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.

Open and recent trials

837 total, page 17 of 17

COMPLETED NA

Determination of the Effect of Extreme Dietary Carbohydrate Restriction on Hepatic Glucose Production

NCT01262326

COMPLETED Phase 4

Effects of Thiazide Diuretics on Sympathetic Nervous System in Hypertension

NCT00353652

COMPLETED Phase 1

Safety Study of ACP-104: To Demonstrate the Safety, Tolerability, and Pharmacokinetics

NCT00628420

COMPLETED NA

Treatment Study Comparing Medium or High Dose Uva-1 Treatment 3x/Week Versus Fluocinonide 0.05% Cream in the Treatment of Morphea.

NCT00812188

COMPLETED NA

A Comparison of 12 Month Daily Wear of Two Novel O2 Permeable Silicone Hydrogel CLs (HOP/SiH) and A Control, Standard O2 Lens

NCT00344643

COMPLETED NA

A Placebo Controlled Double Masked Clinical Assessment Study of Essential Fatty Acid Supplement and Its Effect on Patients With Apparent Aqueous Deficient Dry Eye Syndrome

NCT00344721

COMPLETED NA

Cognitive Behavioral Therapy for Depression Relapse Prevention in Children and Adolescents

NCT00158301

COMPLETED Phase 2

Capecitabine and Radiation Therapy in Treating Patients With Nonmetastatic Breast Cancer After Surgery

NCT00562718

COMPLETED Phase 1

Stereotactic Radiosurgery for Patients With Hepatic Metastases.

NCT00547677

COMPLETED Phase 2

Safety Study of Combination Therapy With Intramuscular Avonex and Oral Cellcept in Patients With Multiple Sclerosis

NCT00223301

COMPLETED

Factors That Influence Compliance With Disease-Modifying Therapy in Multiple Sclerosis

NCT00223457

COMPLETED

Comparison Study of a New Fiberoptic Intubation Device to Standard Intubation Techniques

NCT00906932

COMPLETED

Role of Matrix Metalloproteinases (MMPs) and Tissue Inhibitors of Metalloproteinases (TIMPs) in Children With Myocarditis

NCT00693134

COMPLETED Phase 4

Insulin Resistance and Intramyocellular Lipid Content in Glucose Intolerant Subjects Receiving Rosiglitazone

NCT00746174

COMPLETED Phase 4

Pregnenolone Trial for Depression in Bipolar Disorders or Recurrent Major Depressive Disorder With Substance Abuse

NCT00223197

COMPLETED Phase 4

Impact of Nesiritide Infusion for Decompensated Heart Failure in the Emergency Department

NCT00559338

COMPLETED NA

Preservation of Beta-cell Function in Type 2 Diabetes Mellitus

NCT00232583

COMPLETED Phase 4

Treating Cognition in Schizophrenia With Atomoxetine and Cognitive Remediation

NCT00628394

COMPLETED

Customized Laser Ablation: Comparing Results of LADAR Vision and VISX Platforms

NCT00344838

COMPLETED NA

Fiber Regimens for Constipation Symptoms

NCT03845673

COMPLETED NA

Adding Exercise to Antidepressant Medication Treatment for Depression

NCT00076258

COMPLETED

Impact of Caregiver Depression on Asthma in the Child

NCT00223288

COMPLETED Phase 2

Therapeutic Approaches to HAART-Induced Lipodystrophy

NCT00461552

COMPLETED Phase 3

Impact of Low Dose Naloxone on Fentanyl Requirements in Pediatric ICU Patients

NCT00286052

COMPLETED Phase 4

Quetiapine in Patients With Bipolar and Alcohol Abuse/Dependence

NCT00223249

COMPLETED NA

A Randomized Control Trial Comparing Quetiapine to Risperidone in Bipolar Disorder With Stimulant Dependence

NCT00227123

COMPLETED Phase 4

Clinical Trial of Lamotrigine to Reverse Cognitive Impairment in Chronic Corticosteroid-Treated Patients

NCT00223262

COMPLETED Phase 4

Mechanisms of Lipodystrophy in HIV-Infected Pateints

NCT00457665

COMPLETED Phase 2

Acupuncture as a Supplemental Treatment for Bipolar Depression

NCT00071669

TERMINATED Phase 2

Study Of Two Non-Myeloablative Stem Cell Transplant Strategies For Low-Grade Lymphoma And CLL

NCT00041288

COMPLETED

Macrophage Inhibitory Factor and High-Mobility Group-1 Protein in Children Undergoing Cardiopulmonary Bypass

NCT00692432

COMPLETED NA

Determining Optimal Continuation Treatment Duration for Depressed Children and Adolescents

NCT00332787

COMPLETED Phase 3

Cognitive Therapy for Recurrent Depression

NCT00118404

TERMINATED Phase 2

Tamoxifen in Preventing Breast Cancer in Women at Increased Risk for Breast Cancer

NCT00096369

COMPLETED Phase 2

Total-Body Irradiation, Fludarabine, and Peripheral Stem Cell Transplantation in Treating Patients With Hematologic Cancer

NCT00044954

COMPLETED Phase 1

Gene Therapy in Treating Patients With Advanced Recurrent or Persistent Ovarian Cancer or Primary Peritoneal Cancer

NCT00003450

COMPLETED NA

Lipid, Glycemic, and Insulin Responses to Meals Rich in Different Fatty Acids

NCT00479791

← Previous Page 17 of 17

Phase Distribution

PhaseTrial count
Phase 1 106
Phase 2 122
Phase 3 28
Phase 4 98

What is open in the University of Texas Southwestern Medical Center pipeline

162 recruiting of 837 indexed (19% open); 503 completed (60%).

Phase mix: 126 late (III/IV) vs 228 early (I/II) (early-phase heavy).

Top condition: Hypertension (9 trials), 9 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

University of Texas Southwestern Medical Center: open-pipeline peers nationwide

Peers matched on 837 registered trials and 19% open enrollment, not the therapeutic-area sidebar.

University of Texas Southwestern Medical Center sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 02004006008001,000 14%16%18%20%22% Total trials Recruiting share University of Texas Southwestern Medical CenterUniversity of UtahUniversity of ChicagoIndiana UniversityDana-Farber Cancer InstituteCalifornia Polytechnic State University-San Luis ObispoPhoenix Children's HospitalAnn & Robert H Lurie Children's Hospital of ChicagoVanderbilt University Medical Center
University of Texas Southwestern Medical Center sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

University of Texas Southwestern Medical Center sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 837 trials (± recruiting share)

Sponsors near 19% open enrollment (± trial volume)

What to do with this University of Texas Southwestern Medical Center page

837 registered trials is a research-attention snapshot, not an endorsement of University of Texas Southwestern Medical Center or any single study.

  • 162 of University of Texas Southwestern Medical Center's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Hypertension is the condition University of Texas Southwestern Medical Center studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Hypertension trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

University of Texas Southwestern Medical Center pipeline card: 837 registered trials from official public datasets.Report a data error.